Patents by Inventor David Haffner
David Haffner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10828195Abstract: Devices and methods for treating intraocular pressure are disclosed. The devices include shunts for draining aqueous humor from the anterior chamber to the uveoscleral outflow pathway, including the supraciliary space and the suprachoroidal space. The shunts are preferably implanted by ab interno procedures.Type: GrantFiled: May 4, 2018Date of Patent: November 10, 2020Assignee: Glaukos CorporationInventors: Thomas W. Burns, David Haffner, Harold A. Heitzmann, Todd N. Fjield, Richard A. Hill
-
Publication number: 20180325732Abstract: Devices and methods for treating intraocular pressure are disclosed. The devices include shunts for draining aqueous humor from the anterior chamber to the uveoscleral outflow pathway, including the supraciliary space and the suprachoroidal space. The shunts are preferably implanted by ab interno procedures.Type: ApplicationFiled: May 4, 2018Publication date: November 15, 2018Inventors: Thomas W. Burns, David Haffner, Harold A. Heitzmann, Todd N. Fjield, Richard A. Hill
-
Patent number: 9962290Abstract: Devices and methods for treating intraocular pressure are disclosed. The devices include shunts for draining aqueous humor from the anterior chamber to the uveoscleral outflow pathway, including the supraciliary space and the suprachoroidal space. The shunts are preferably implanted by ab interno procedures.Type: GrantFiled: August 12, 2013Date of Patent: May 8, 2018Assignee: Glaukos CorporationInventors: Thomas W. Burns, David Haffner, Harold A. Heitzmann, Todd N. Fjield, Richard A. Hill
-
Publication number: 20180028361Abstract: Devices and methods for treating intraocular pressure are disclosed. The devices include drug delivery implants for treating ocular tissue. Optionally, the devices also include shunts for draining aqueous humor from the anterior chamber to the uveoscleral outflow pathway, including the supraciliary space and the suprachoroidal space. The drug delivery implants can be implanted in ab interno or ab externo procedures.Type: ApplicationFiled: March 28, 2017Publication date: February 1, 2018Inventors: David Haffner, Kenneth Curry
-
Patent number: 9668915Abstract: Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.Type: GrantFiled: November 22, 2011Date of Patent: June 6, 2017Assignee: DOSE MEDICAL CORPORATIONInventors: David Haffner, Ken Curry, Harold Heitzmann, David Applegate
-
Patent number: 9636255Abstract: Devices and methods for treating intraocular pressure are disclosed. The devices include drug delivery implants for treating ocular tissue. Optionally, the devices also include shunts for draining aqueous humor from the anterior chamber to the uveoscleral outflow pathway, including the supraciliary space and the suprachoroidal space. The drug delivery implants can be implanted in ab interno or ab externo procedures.Type: GrantFiled: February 12, 2010Date of Patent: May 2, 2017Assignee: DOSE MEDICAL CORPORATIONInventors: David Haffner, Kenneth Curry
-
Patent number: 9220632Abstract: Methods of treating ocular disorders are disclosed, including: inserting an implant in eye tissue, using an instrument, such that an inlet portion of the implant is in an anterior chamber of an eye and an outlet portion of the implant is in a physiological outflow pathway; removing the instrument from the eye without removing the implant; and conducting fluid comprising a therapeutic substance through the implant and into the physiological outflow pathway. Another method includes inserting an instrument into a physiologic outflow pathway through which aqueous humor drains from an anterior chamber of an eye; separating first and second walls of tissues which comprise the physiologic outflow pathway by injecting a fluid comprising a drug from the instrument while the instrument remains in the physiologic outflow pathway; and withdrawing the instrument with said fluid remaining within the eye such that the drug has a therapeutic effect on the eye.Type: GrantFiled: December 20, 2013Date of Patent: December 29, 2015Assignee: GLAUKOS CORPORATIONInventors: Gregory Smedley, David Haffner, Hosheng Tu
-
Publication number: 20150223981Abstract: A method is provided for treatment of cataract in combination with a glaucoma procedure while maintaining the intraocular pressure by permitting aqueous to flow out of an anterior chamber of the eye through a surgically stented pathway. A trabecular stent is adapted for implantation within the trabecular meshwork of an eye such that intraocular liquid flows controllably from the anterior chamber of the eye to Schlemm's canal, bypassing the trabecular meshwork. Depending upon the specific treatment contemplated, pharmaceuticals may be utilized in conjunction with the trabecular stent enabling post-cataract healing processes.Type: ApplicationFiled: November 10, 2014Publication date: August 13, 2015Inventors: Gregory T. Smedley, David Haffner, Barbara Niksch, Hosheng Tu, Thomas W. Burns
-
Patent number: 8882781Abstract: A method is provided for treatment of cataract in combination with a glaucoma procedure while maintaining the intraocular pressure by permitting aqueous to flow out of an anterior chamber of the eye through a surgically stented pathway. A trabecular stent is adapted for implantation within the trabecular meshwork of an eye such that intraocular liquid flows controllably from the anterior chamber of the eye to Schlemm's canal, bypassing the trabecular meshwork. Depending upon the specific treatment contemplated, pharmaceuticals may be utilized in conjunction with the trabecular stent enabling post-cataract healing processes.Type: GrantFiled: May 27, 2011Date of Patent: November 11, 2014Assignee: Glaukos CorporationInventors: Gregory T Smedley, David Haffner, Barbara Niksch, Hosheng Tu, Thomas W Burns
-
Publication number: 20140081194Abstract: Devices and methods for treating intraocular pressure are disclosed. The devices include shunts for draining aqueous humor from the anterior chamber to the uveoscleral outflow pathway, including the supraciliary space and the suprachoroidal space. The shunts are preferably implanted by ab interno procedures.Type: ApplicationFiled: August 12, 2013Publication date: March 20, 2014Applicant: GLAUKOS CORPORATIONInventors: Thomas W. Burns, David Haffner, Harold A. Heitzmann, Todd N. Fjield, Richard A. Hill
-
Patent number: 8617094Abstract: Methods of treating ocular disorders are disclosed, such as a method that includes inserting an implant in eye tissue, using a delivery instrument, such that an inlet portion of the implant is in an anterior chamber of an eye and an outlet portion of the implant is in a physiological outflow pathway; removing the delivery instrument from the eye without removing the implant; and conducting fluid comprising a therapeutic substance through the implant and into the physiological outflow pathway. Another method includes inserting an instrument into a physiologic outflow pathway through which aqueous humor drains from an anterior chamber of an eye; separating first and second walls of tissues which comprise the physiologic outflow pathway by injecting a fluid comprising a drug from the instrument while the instrument remains in the physiologic outflow pathway; and withdrawing the instrument following the injection with said fluid remaining within the eye such that the drug has a therapeutic effect on the eye.Type: GrantFiled: January 12, 2006Date of Patent: December 31, 2013Assignee: Glaukos CorporationInventors: Gregory Smedley, David Haffner, Hosheng Tu
-
Patent number: 8579846Abstract: Implants and methods for treating ocular disorders are disclosed. One implant has a tubular member, with inlet and outlet ends, and a cutting member connected thereto. The tubular member is configured to extend through eye tissue such that the inlet and outlet ends reside respectively in an anterior chamber and a physiologic outflow pathway of the eye. Desirably, the cutting member is configured to make an incision in the eye tissue for receiving at least a portion of the tubular member. One method involves introducing an implant, with proximal and distal ends, into the anterior chamber and penetrating eye tissue using an implant distal portion. The implant is advanced from the anterior chamber into the penetrated eye tissue to locate the distal and proximal ends respectively in the physiologic outflow pathway and the anterior chamber. Aqueous humor is conducted between the proximal and distal ends.Type: GrantFiled: November 21, 2011Date of Patent: November 12, 2013Assignee: Glaukos CorporationInventors: Hosheng Tu, Gregory T. Smedley, David Haffner, Barbara A. Niksch
-
Publication number: 20130289467Abstract: Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.Type: ApplicationFiled: November 22, 2011Publication date: October 31, 2013Inventors: David Haffner, Ken Curry, Harold Heitzmann, David Applegate
-
Patent number: 8506515Abstract: Devices and methods for treating intraocular pressure are disclosed. The devices include shunts for draining aqueous humor from the anterior chamber to the uveoscleral outflow pathway, including the supraciliary space and the suprachoroidal space. The shunts are preferably implanted by ab interno procedures.Type: GrantFiled: November 9, 2007Date of Patent: August 13, 2013Assignee: Glaukos CorporationInventors: Thomas W. Burns, David Haffner, Harold A. Heitzmann, Todd N. Fjield, Richard A. Hill
-
Patent number: 8348877Abstract: Implants and methods for treating ocular disorders are provided. One method involves introducing an implant into an anterior chamber of an eye such that at least a distal end of the implant is temporarily in the anterior chamber. The implant is implanted into eye tissue adjacent the anterior chamber. A therapeutic agent is eluted from the implant into at least one of the anterior chamber, a physiologic outflow pathway of the eye, and a space adjacent a choroid of the eye. The therapeutic agent can be an antiproliferative agent, an anti-inflammatory drug, or a compound for treating glaucoma or ocular hypertension. The therapeutic agent can be contained within the implant or coated on the implant.Type: GrantFiled: May 3, 2010Date of Patent: January 8, 2013Assignee: Dose Medical CorporationInventors: Hosheng Tu, Barbara Niksch, David Haffner, Gregory Smedley, Olav B Bergheim, Morteza Gharib
-
Publication number: 20120253258Abstract: Ocular implants, delivery devices and methods for treating ocular disorders are disclosed. One method involves inserting an implant on one side of an eye. The implant has an anchor on a distal end portion and an outlet opening that is disposed proximal of the anchor. The implant is advanced across the eye to the other side of the eye. The anchor is inserted into eye tissue on the other side of the eye. A therapeutic agent is eluted using the implant.Type: ApplicationFiled: February 17, 2012Publication date: October 4, 2012Applicant: DOSE MEDICAL CORPORATIONInventors: Hosheng Tu, Jason Artof, David Haffner
-
Publication number: 20120165933Abstract: Devices and methods for treating intraocular pressure are disclosed. The devices include drug delivery implants for treating ocular tissue. Optionally, the devices also include shunts for draining aqueous humor from the anterior chamber to the uveoscleral outflow pathway, including the supraciliary space and the suprachoroidal space. The drug delivery implants can be implanted in ab interno or ab externo procedures.Type: ApplicationFiled: February 12, 2010Publication date: June 28, 2012Applicant: DOSE MEDICAL CORPORATIONInventors: David Haffner, Kenneth Curry
-
Publication number: 20120109040Abstract: A method is provided for treatment of cataract in combination with a glaucoma procedure while maintaining the intraocular pressure by permitting aqueous to flow out of an anterior chamber of the eye through a surgically stented pathway. A trabecular stent is adapted for implantation within the trabecular meshwork of an eye such that intraocular liquid flows controllably from the anterior chamber of the eye to Schlemm's canal, bypassing the trabecular meshwork. Depending upon the specific treatment contemplated, pharmaceuticals may be utilized in conjunction with the trabecular stent enabling post-cataract healing processes.Type: ApplicationFiled: May 27, 2011Publication date: May 3, 2012Applicant: GLAUKOS CORPORATIONInventors: Gregory T. Smedley, David Haffner, Barbara Niksch, Hosheng Tu, Thomas W. Burns
-
Publication number: 20120078362Abstract: Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allows for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.Type: ApplicationFiled: May 18, 2010Publication date: March 29, 2012Applicant: DOSE MEDICAL CORPORATIONInventors: David Haffner, Ken Curry, Harold Heitzmann, David Applegate
-
Publication number: 20120071809Abstract: Implants and methods for treating ocular disorders are disclosed. One implant has a tubular member, with inlet and outlet ends, and a cutting member connected thereto. The tubular member is configured to extend through eye tissue such that the inlet and outlet ends reside respectively in an anterior chamber and a physiologic outflow pathway of the eye. Desirably, the cutting member is configured to make an incision in the eye tissue for receiving at least a portion of the tubular member. One method involves introducing an implant, with proximal and distal ends, into the anterior chamber and penetrating eye tissue using an implant distal portion. The implant is advanced from the anterior chamber into the penetrated eye tissue to locate the distal and proximal ends respectively in the physiologic outflow pathway and the anterior chamber. Aqueous humor is conducted between the proximal and distal ends.Type: ApplicationFiled: November 21, 2011Publication date: March 22, 2012Applicant: Glaukos CorporationInventors: Hosheng Tu, Gregory T. Smedley, David Haffner, Barbara A. Niksch